ICIs n=446 | MAPKi n=222 | Overall n=668 | |
BMI continuous | |||
Mean (SD) | 27.1 (5.0) | 27.0 (4.7) | 27.1 (4.9) |
Median (Q1 to Q3) | 26.3 (23.7 to 29.7) | 26.3 (23.7 to 29.7) | 26.3 (23.7 to 29.7) |
Min to max | 14.8 to 50.4 | 17.8 to 41.0 | 14.8 to 50.4 |
BMI class, n (%) | |||
Normal (BMI <25) | 166 (37.2) | 83 (37.4) | 249 (37.3) |
Overweight (BMI (25 to 30)) | 176 (39.5) | 85 (38.3) | 261 (39.1) |
Obese (BMI≥30) | 104 (23.3) | 54 (24.3) | 158 (23.7) |
Gender, n (%) | |||
Female | 174 (39.0) | 99 (44.6) | 273 (40.9) |
Male | 272 (61.0) | 123 (55.4) | 395 (59.1) |
Age | |||
Mean (SD) | 63.5 (13.4) | 56.9 (13.1) | 61.3 (13.6) |
Median (Q1 to Q3) | 65.5 (54.3 to 73.7) | 57.5 (47.7 to 66.7) | 62.1 (52.2 to 71.5) |
Min to max | 22.9 to 93.1 | 23.0 to 91.1 | 22.9 to 93.1 |
BRAF mutation, n (%) | |||
Negative | 373 (84.4) | 0 (0.0) | 373 (56.2) |
Positive | 69 (15.6) | 222 (100) | 291 (43.8) |
Missing | 4 | 0 | 4 |
Disease stage, n (%) | |||
M1a+M1b | 205 (46.4) | 80 (36.0) | 285 (42.9) |
M1c+M1d | 237 (53.6) | 142 (64.0) | 379 (57.1) |
Missing | 4 | 0 | 4 |
LDH values, n (%) | |||
0 | 304 (70.9) | 112 (50.9) | 416 (64.1) |
≥1 | 125 (29.1) | 108 (49.1) | 233 (35.9) |
Missing | 17 | 2 | 19 |
ECOG PS values, n (%) | |||
0 | 262 (59.0) | 98 (44.1) | 360 (54.1) |
≥1 | 182 (41.0) | 124 (55.9) | 306 (45.9) |
Missing | 2 | 0 | 2 |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group Performance Status; ICIs, immune checkpoint inhibitors; LDH, lactate dehydrogenase; MAPKi, mitogen activated pathway kinase inhibitors; Max, maximum; Min, minimum; n, number of subjects; Q, quartile.